Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings

Haemonetics (HAE) is scheduled to report first-quarter fiscal 2025 results on Aug 8, before market open. In the last reported quarter, the company's adjusted earnings per share (EPS) of 90 cents surpassed the Zacks Consensus Estimate by 2.27%. The Zacks Consensus Estimate for EPS of $1.03 indicates a year-over-year decline of 1.9%. Let's take a look at how things might have shaped up for the MedTech major prior to the announcement. Hospital revenues in the fiscal first quarter are once again expected to hav ...